Reversible painful oral mucosal hyperpigmentation following palifermin administration

Acta Haematologica

Volumn 124, Issue 3, 2010, Pages 185-187

  Kaloyannidis, Panayotis ^a   Papalexandri, Apostolia ^a   Papaemanouil, Evangelia ^a   Papaioannou, Maria ^b   Sakellari, Ioanna ^a  

^a G PAPANICOLAOU HOSPITAL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DEXAMETHASONE; MELPHALAN; PALIFERMIN; THALIDOMIDE;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CASE REPORT; DRUG ERUPTION; HISTOPATHOLOGY; HUMAN; HYPERPIGMENTATION; MAINTENANCE THERAPY; MALE; MOUTH LESION; MOUTH PAIN; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; PRIORITY JOURNAL;

FIBROBLAST GROWTH FACTOR 7; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYPERPIGMENTATION; MALE; MIDDLE AGED; MOUTH MUCOSA; MULTIPLE MYELOMA; PAIN; RECOMBINANT PROTEINS; STOMATITIS;

EID: 77958017540     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000318835     Document Type: Article

References (9)

1. Blijlevens N, Sonis S: Palifermin (recombinant keratinocyte growth factor-1): a pleiotropic growth factor with multiple biological activities in preventing chemotherapy-and radiotherapy-induced mucositis. Ann Oncol 2007;18:817-826.
2. Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, Migliorati CA, McGuire DB, Hutchins RD, Peterson DE: Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer 2007;109:820-831.
3. Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T, Shea T, Yanovich S, Hansen K, Noga S, McCarty J, LeMaistre CF, Sung EC, Blazar BR, Elhardt D, Chen MG, Emmanouilides C: Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004;351:2590-2598.
4. Lane SW, Manoharan S, Mollee PN: Palifermin-induced acanthosis nigricans. Intern Med J 2007;37:417-418.
5. Sibelt LA, Aboosy N, van der Velden WJ, Blijlevens NM, Blokx WA, Seyger MM: Palifermin-induced flexural hyperpigmentation: a clinical and histological study of five cases. Br J Dermatol 2008;159:1200-1203.
6. Cardinali G, Bolasco G, Aspite N, Lucania G, Lotti LV, Torrisi MR, Picardo M: Melanosome transfer promoted by keratinocyte growth factor in light and dark skin-derived keratinocytes. J Invest Dermatol 2008;128:558-567.
7. Alderson R, Gohari-Fritsch S, Olsen H, Roschke V, Vance C, Conolly K: In vitro and in vivo effects of rapifermin (keratinocyte growth factor-2, KGF-2) on human carcinoma cells. Cancer Chemother Pharmacol 2002;50:202-212.
8. Ning S, Shui C, Khan WB, Benson W, Lacey DL, Knox SJ: Effects of keratinocyte growth factor on the proliferation and radiation survival of human squamous cell carcinoma cell lines in vitro and in vivo. Int J Radiat Oncol Biol Phys 1998;40:177-187.
9. Gartside MG, Chen H, Ibrahimi OA, Byron SA, Curtis AV, Wellens CL, Bengston A, Yudt LM, Eliseenkova AV, Ma J, Curtin JA, Hyder P, Harper UL, Riedesel E, Mann GJ, Trent JM, Bastian BC, Meltzer PS, Mohammadi M, Pollock PM: Loss of function fibroblast growth factor receptor-2 mutations in melanoma. Mol Cancer Res 2009;7:41-54.